<unk> (injection) is an antineoplastic agent that is FDA approved for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include myelosuppression (neutropenia, thrombocytopenia and anemia), fever and chills, infection, and nausea and vomiting. Other commonly reported events include malaise, fatigue, anorexia, and weakness.
Fludarabine 
Vidarabine
Clofarabine
Nelarabine
Cladribine
Cytarabine
Mafosfamide
Floxuridine